Catheter Precision, Inc. (NYSEAMERICAN:VTAK) Short Interest Up 606.2% in June

Catheter Precision, Inc. (NYSEAMERICAN:VTAK) was the target of a significant increase in short interest in June. As of June 30th, there was short interest totaling 289,957 shares, an increase of 606.2% from the June 15th total of 41,058 shares. Based on an average daily trading volume, of 18,514,293 shares, the days-to-cover ratio is presently 0.0 days. Currently, 8.5% of the company’s stock are sold short.

Hedge Funds Weigh In On Catheter Precision

A hedge fund recently bought a new stake in Catheter Precision stock. Millennium Management LLC purchased a new stake in shares of Catheter Precision, Inc. (NYSEAMERICAN:VTAK) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned 2.08% of Catheter Precision as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 20.34% of the company’s stock.

Catheter Precision Stock Down 11.8%

VTAK stock traded down $0.09 during mid-day trading on Monday, hitting $0.70. 798,067 shares of the company were exchanged, compared to its average volume of 3,689,726. The firm has a fifty day simple moving average of $0.92 and a 200 day simple moving average of $1.32. The company has a market capitalization of $2.52 million, a PE ratio of -0.05 and a beta of -1.07. Catheter Precision has a twelve month low of $0.61 and a twelve month high of $4.94. The company has a current ratio of 0.06, a quick ratio of 0.06 and a debt-to-equity ratio of 0.35.

Catheter Precision (NYSEAMERICAN:VTAK) last announced its quarterly earnings data on Monday, May 18th. The company reported ($1.39) earnings per share for the quarter, beating the consensus estimate of ($20.90) by $19.51. Catheter Precision had a negative return on equity of 76.51% and a negative net margin of 1,297.56%.The firm had revenue of $0.43 million during the quarter, compared to analyst estimates of $1.60 million.

Catheter Precision Company Profile

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.